Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a AG011 dose-escalation study in moderately active ulcerative colitis
2008-000967-40Phase 2Active
- Sponsor
- ActoBio Therapeutics
- Start
- May 2008
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in autoimmune colitis comparing AG011 with Placebo (2 arms). Primary endpoint: Safety and tolerability of AG011. Started May 2008; status: active.
02
Drugs
AG011
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2008-000967-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-000967-40.